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Objectives: To evaluate the cost-effectiveness of propofol compared to midazolam in
mechanically ventilated (MVd) critically ill adult patients. PERSPECTIVE OF THE
ANALYSIS Brazilian private health care system. Methods: A decision tree model was
built to reflect the hospitalization of a MVd critically ill clinical patient. The time
horizon was that of a ICU hospitalization, and the outcomes were cost effectiveness
per hour of reduced ICU stay and cost effectiveness per hour of MV avoided. Data to
populate the model came from a meta-analysis. The model was built based on the
meta-analytic difference in the mean length of ICU stay and MV time. It was
established that the cost of medication was embedded in the ICU cost, and that the
daily ICU cost was the same in both arms. Univariate and probabilistic sensitivity
analysis was performed. Results: Propofol use in MVd critically ill adult patients
decreased ICU stay in 47.97 hours and 21.65 hours of MV. There was a cost reduction
of R$ 4,397.25 when compared to midazolam. The cost-effectiveness per hour of ICU
stay and MV time avoided was dominant in 94.70% and in 80.87% of the time,
respectively. Conclusions: Propofol may be the preferred choice for mechanically
ventilated critically ill adult patients, reducing ICU stay and MV time.
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Objectives: Assessing cost-effectiveness for new interventions against comparators
for which only single-arm trials are present raises some methodological issues.
Methods like Matching-Adjusted-Indirect-Comparisons (MAIC) "align” the popula-
tion characteristics across the interventions within the trials, hence provide a
framework for head-to-head indirect comparison. The presence of potential cures
raises further issues. Methods: We apply a sequential statistical framework con-
sisting of the following steps: estimate the patient-specific weights for the inter-
vention of interest with a MAIC approach, returning a set of patient-specific weights
for the population of the intervention of interest adjusted to the population of the
relevant comparator; apply cure-estimations on the weighted intervention of in-
terest - via a weighted maximum likelihood approach - and on the unweighted
comparators; include options in the cost-effectiveness model to allow for the se-
lection of the relevant parameters (e.g. coefficients of parametric extrapolations, cure
estimates etc) of interest. Results: Our sequential approach offers the opportunity to
assess the cost-effectiveness of a new intervention against a pool of comparators in
the absence of a connected network of indirect comparisons. The user can select
pairs of treatments and determine the relative cost-effectiveness of one versus the
other. Furthermore, the estimation of uncertainties around the parameter estimates
(inflated because of the effective sample size resulting from the population-matching
exercise) provide a valuable tool to perform Probabilistic Sensitivity Analyses. Con-
clusions: Although we are modifying the population of the intervention within the
trial to match the one of the comparators selected, we are providing a solid frame-
work to assess the relative efficacy of a new intervention. Current limitations of the
approach include: the inability to assess the cost-effectiveness plane as a whole, as
the baseline characteristics are adjusted for each pairs of comparators chosen; high
variations in the relative effectiveness due to shrinking the effective sample size with
the MAIC exercise.
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Objectives: To review the evidence of out-of-pocket (OOPE) and catastrophic ex-
penditures (CHE) in health in Colombia. Methods: Systematic review of the litera-
ture (SLR). Searches were performed in PubMed, Scopus, Scielo and Google Scholar.
We used the MESH terms: out-of-pocket, catastrophic health expenditure, health
and Colombia. We included cost description or cost analysis studies. Cost-effective-
ness analysis of health technologies and qualitative studies were excluded. Data
about period of analysis, type of study, costing perspective, OOPE, and CHE were
extracted. Studies were classified as macroeconomic, microeconomic, and diseases
analysis. All costs were indexed to 2018 and reported in Colombian pesos (COP).
Results: We found 44 studies, 15 were duplicated. Twenty full-text papers were
revised and 17 were finally included. Six studies were prospective, seven from pa-
tient perspective and four from societal perspective. Only five studies estimated CHE.
Macroeconomic analysis: between 1993-2011, the average OOPE was 18% of total
health expenditure and 1.1% of Colombian GDP. Microeconomic analysis: Amaya
(2016) identified Pacific region as the most vulnerable, with a CHE of 16,9%, ten
percentage points higher than Bogotá (lowest CHE). If a woman was head of
household, their OOPE increased by 14%. Members of the households at extreme ages
augmented the OOPE; if they were children under-5, health expenses increased by
15%, and if they were elderly, by 21%. Disease analysis: OOPE of Chikungunya (3.3%
out of the total costs of the disease), HIV (monthly OOPE in antiretroviral therapy:
COP$237.153), dengue (OOPE of COP$54.672 per hospitalization), and arterial
hypertension (COP$44.548 per cardiac rehabilitation session). Conclusions: OOPE
and CHE are not frequently estimated in Colombian health economic studies. Doc-
uments reviewed reflect the heterogeneity of the studies. Data sources do not offer
availability of data over the time and non-standardized methodologies were
frequent.
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Objectives: Over $27 million is spent by US hospitals on annual drug spend. Roughly
20% of hospital drug inventory is wasted or expires each year. Additionally, 50% of
hospitals report manual drug inventory management methods. We created a cost-
benefit model to predict the impact of a pharmacy management predictive analytics
software on inventory costs. Methods: A cost-benefit model was created using
Microsoft Excel to predict the economic impact of a pharmacy management predictive
analytics software. Predictedbenefitwas calculatedusing a combination of drugcost data
and drug utilization data. Three areas of cost-benefit were assumed: inventory reduction
in patient care areas and central pharmacy, respectively, and reduction in wasted medi-
cationfrommoreefficientmanagementofmin/max inventory levels. Inventory reduction
was assumed to bea one-time cost-benefit,whereas savingsdue towaste reductionwere
repeated yearly. Cost was defined as the cost of the predictive analytics program. We
analyzed cost-benefit over a five-year period using a large cohort of US acute-care hos-
pitals. Results: 61 acute-care hospitals were included in the cost-benefit analysis. The
majority were located in the southeast (64%), had a bed size of 101-250 beds (44%), and
were non-academic (39%). The model estimated annual medication spend ranging from
$335,551 - $309,712,416 (median=$6,853,533). Ranges of estimated inventory re-
ductions in patient care areas and central pharmacy were $3,000-$569,000 (me-
dian=$56,000) and $0-$1,851,000 (median=$13,500), respectively. Median projected
yearly savings fromwaste reductionwere $63,000 ($8,000-$1,443,000). Over a five-year
period, cumulative cost-benefit rose from a median of $101,000 (year one) to $344,185
(year five). Estimated median ROI from adopting the intervention at year one and year
five was 2.52 and 3.0, respectively. Conclusions: Predicted cost savings with the use of
an analytics program potentially led to a five-year cumulative cost-benefit of $344,185
and a five-year ROI of 3.0. Future research should be performed to assess true/actual
cost-benefit.
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Objectives: For drugs approved in multiple conditions, current product-specific
pricing frameworks struggle to reflect differences in efficacy and value across in-
dications accurately. Value-based pricing (VBP) approaches based on a drug’s value
in a single indication (e.g., first approval, minimum value) may negatively affect
patients’ access to effective therapies in other indications (e.g., payers restricting
coverage, manufacturers forgoing new indications). Health technology appraisal
bodies have responded by recommended a weighted-average VBP approach. This
study aims to demonstrate the impact of alternative weighting methodologies on
cross-indication VBP estimates. Methods: We considered three weighting methods:
(1) based on the incidence of each indication, (2) based on the number of patients
using the drug for each indication (reflecting incidence and market share), and (3)
based on the total drug utilization for each indication (reflecting incidence, market
share, and drug utilization per patient). To demonstrate the use of these methods, we
considered a hypothetical drug approved in four indications. For each indication,
incidence rates (5, 3, 1, and 0.5 per 1,000 individuals), market shares for the drug
(10%, 60%, 90%, and 40%), average lifetime utilization per patient (40, 20, 60, and 80
units), and VBP estimates for the drug ($2,500, $500, $1,000, and $4,000 per unit)
were assumed. Results: In this example, the cross-indication VBP estimates for the
hypothetical drug using the three weighting methods were $1,789, $1,132, and $1,476
per unit, respectively. Compared with strictly incidence-based weights, incorpo-
rating market share resulted in a 37% reduction in the weighted VBP estimate while
incorporating market share and drug utilization resulted in a smaller 18% reduction
in the weighted VBP estimate. Conclusions: This study underscores the challenges in
capturing the true value to health care systems of drugs with multiple indications
and highlights the importance of including epidemiology, market share, and drug
utilization in cross-indication VBP estimates.
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